Published in Arterioscler Thromb Vasc Biol on December 22, 2005
Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol (2009) 6.11
Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett (2008) 2.98
Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35
Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol (2007) 1.78
Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol (2009) 1.65
Retracted Prospects and applications of nanobiotechnology: a medical perspective. J Nanobiotechnology (2012) 1.54
Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett (2008) 1.47
MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol (2008) 1.32
Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn Reson Med (2006) 1.25
Noninvasive imaging of apoptosis in cardiovascular disease. Heart Fail Rev (2008) 1.11
Quantitative magnetic resonance fluorine imaging: today and tomorrow. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.00
Polymeric Nanostructures for Imaging and Therapy. Chem Rev (2015) 0.99
Angiogenesis is required for stress fracture healing in rats. Bone (2012) 0.95
Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug. Nanomedicine (Lond) (2012) 0.91
Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson (2008) 0.90
Biomarkers of atherosclerosis and the potential of MRI for the diagnosis of vulnerable plaque. MAGMA (2007) 0.90
Quantifying the evolution of vascular barrier disruption in advanced atherosclerosis with semipermeant nanoparticle contrast agents. PLoS One (2011) 0.90
Advances in molecular imaging of atherosclerotic vascular disease. Curr Opin Cardiol (2008) 0.85
Critical evaluation of biodegradable polymers used in nanodrugs. Int J Nanomedicine (2013) 0.84
Inflammation in cardiovascular tissue engineering: the challenge to a promise: a minireview. Int J Inflam (2011) 0.84
Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function. FASEB J (2014) 0.84
Inorganic nanocrystals as contrast agents in MRI: synthesis, coating and introduction of multifunctionality. NMR Biomed (2013) 0.83
Antagonizing the αv β3 integrin inhibits angiogenesis and impairs woven but not lamellar bone formation induced by mechanical loading. J Bone Miner Res (2014) 0.80
TSPO targeted dendrimer imaging agent: synthesis, characterization, and cellular internalization. Bioconjug Chem (2009) 0.80
Insights into atherosclerosis using nanotechnology. Curr Atheroscler Rep (2010) 0.80
Antithrombin nanoparticles improve kidney reperfusion and protect kidney function after ischemia-reperfusion injury. Am J Physiol Renal Physiol (2015) 0.78
Echographic imaging of tumoral cells through novel nanosystems for image diagnosis. World J Radiol (2014) 0.75
Nanomedicine: Addressing Cardiovascular Disease and Cardiovascular Tissue Regeneration. Curr Bioact Compd (2016) 0.75
TARGETING OF MACROPHAGE FOAM CELLS IN ATHEROSCLEROTIC PLAQUE USING OLIGONUCLEOTIDE-FUNCTIONALIZED NANOPARTICLES. Nano Life (2010) 0.75
Nanoengineering of therapeutics for retinal vascular disease. Eur J Pharm Biopharm (2015) 0.75
Nanorobotic Applications in Medicine: Current Proposals and Designs. Am J Robot Surg (2014) 0.75
Current status of nanomedicine and nanosurgery. Anesth Essays Res (2015) 0.75
19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J (2007) 2.63
Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 2.45
Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging (2007) 1.46
Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng (2009) 1.39
In vitro demonstration using 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest Radiol (2006) 1.29
High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol (2009) 1.15
Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine (Lond) (2006) 1.13
1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles. Curr Top Dev Biol (2005) 1.10
Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. Int J Nanomedicine (2007) 1.09
Potential role of three-dimensional rotational angiography and C-arm CT for valvular repair and implantation. Int J Cardiovasc Imaging (2011) 1.02
Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery. Curr Pharm Biotechnol (2004) 0.94
Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by (19)F NMR of VCAM-1 targeted nanobeacons. Nanomedicine (2009) 0.90
Improved signal processing to detect cancer by ultrasonic molecular imaging of targeted nanoparticles. J Acoust Soc Am (2011) 0.90
Quantifying the evolution of vascular barrier disruption in advanced atherosclerosis with semipermeant nanoparticle contrast agents. PLoS One (2011) 0.90
Thrombin-inhibiting nanoparticles rapidly constitute versatile and detectable anticlotting surfaces. Nanotechnology (2014) 0.84
Fast retrospectively triggered local pulse-wave velocity measurements in mice with CMR-microscopy using a radial trajectory. J Cardiovasc Magn Reson (2013) 0.83
Nanomedicine opportunities in cardiology. Ann N Y Acad Sci (2006) 0.82
Myocardial perfusion quantification using the T1 -based FAIR-ASL method: the influence of heart anatomy, cardiopulmonary blood flow and look-locker readout. Magn Reson Med (2013) 0.77
The 4th Annual Meeting of the American Society for Nanomedicine. J Neuroimmune Pharmacol (2014) 0.75